


## Kidney Advisory Group ODT Clinical Governance Report May 2021

### 1. Status – Confidential

### 2. Action Requested

KAG are requested to note the findings within this report.

### 3. Data



### 4. Learning from reports

Below is a summary of the findings and learning from key clinical governance reports submitted to ODT:

**Date reported: March 2021**

Reference: ODT-INC-5401

What was reported?
--------------------

It was reported that 25mls of an incorrect solution (sterile water) was used to perfuse a living donor kidney. Once identified the correct fluid was used to flush the kidney and following discussion it was transplanted into the recipient. The recipient is doing well. Whilst the kidney was found to have a degree of impairment, the evidence indicates this was not related to the incident.
--

Investigation findings and learning:
--------------------------------------

This was investigated by the Trust and found that:

- A designated theatre fridge is stocked with fluids required for kidney transplantation. Prior to this event the fridge was stocked with 1-litre bags of Sterile Water. There were no signs on the outside of the fridge detailing which fluids should be stocked or any labelling sections within the fridge. The fridge was also used and accessed by other theatres.
- There was no identified role with the responsibility to check and replenish the agreed stock levels of fluid within the fridge.
- There was no documented process for setting up and perfusion of a live donor kidney.
- Opportunities were missed in the checking of the perfusion fluid.
- The labelling of the two solutions are similar in appearance.

Recommendations:

- Relocation of the kidney transplant fridge from the corridor to the designated transplantation theatres complex.
- Development of documented processes.
- A review of procurement, storage, and replenishment of all sterile fluids within the Trust in relation to the similar labelling of fluids.
- Audit of the storage of transplantation fluids.
- To follow up with national bodies, MHRA and NHS Improvement in relation to medicines packaged with similar appearances.

## **5. Requirement from KAG**

Note findings in this report.

### **Author**

Claire Mitchell  
ODT Clinical Governance Team